Cargando…

Distribution of HBV genotypes in Poland

AIM OF THE STUDY: To identify distribution of HBV genotypes in particular regions of Poland. MATERIAL AND METHODS: The study included 270 treatment-naïve, HBV-infected individuals, enrolled in 7 centers of Poland. HBV genotyping was performed in 243 of them with the INNO-LiPA HBV Genotyping assay (I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Świderska, Magdalena, Pawłowska, Małgorzata, Mazur, Włodzimierz, Tomasiewicz, Krzysztof, Simon, Krzysztof, Piekarska, Anna, Wawrzynowicz-Syczewska, Marta, Jaroszewicz, Jerzy, Rajewski, Paweł, Zasik, Ewelina, Murias-Bryłowska, Elżbieta, Pniewska, Anna, Halota, Waldemar, Flisiak, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421165/ https://www.ncbi.nlm.nih.gov/pubmed/28856248 http://dx.doi.org/10.5114/ceh.2015.51372

Ejemplares similares

Recommendations for the treatment of hepatitis B in 2017
por: Flisiak, Robert, et al.
Publicado: (2017)

Searching for the optimal population for hepatitis C virus screening in Poland
por: Piekarska, Anna, et al.
Publicado: (2020)

Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2018)

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2023)

Recommendations for the treatment of hepatitis C in 2017
por: Halota, Waldemar, et al.
Publicado: (2017)

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020
por: Halota, Waldemar, et al.
Publicado: (2020)

Recommendations for the treatment of hepatitis C issued by the Polish Group of HCV Experts – 2016
por: Halota, Waldemar, et al.
Publicado: (2016)

Recommendations for treatment of hepatitis C. Polish Group of HCV Experts – 2015
por: Halota, Waldemar, et al.
Publicado: (2015)

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study
por: Rajewski, Paweł, et al.
Publicado: (2022)

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study
por: Rajewski, Paweł, et al.
Publicado: (2022)

Continuous up to 4 Years Entecavir Treatment of HBV-Infected Adolescents – A Longitudinal Study in Real Life
por: Pawłowska, Małgorzata, et al.
Publicado: (2016)

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study
por: Janczewska, Ewa, et al.
Publicado: (2018)

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus
por: Domagalski, Krzysztof, et al.
Publicado: (2016)

Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation
por: Pawłowska, Małgorzata, et al.
Publicado: (2019)

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study
por: Janczewska, Ewa, et al.
Publicado: (2021)

Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C – a real-world study
por: Simon, Krzysztof Adam, et al.
Publicado: (2019)

Prevalence of hepatitis delta infections among HBs-antigen-positive inhabitants of southeastern and northwestern parts of Poland
por: Pleśniak, Robert, et al.
Publicado: (2019)

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens
por: Tronina, Olga, et al.
Publicado: (2023)

Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study
por: Tronina, Olga, et al.
Publicado: (2021)

Effect of psoriasis activity on serum adiponectin and leptin levels
por: Baran, Anna, et al.
Publicado: (2015)

Immune regulation and viral diversity as correlates of natural and treatment induced immune control in persistent hepatitis B virus (HBV) infection
por: Parfieniuk-Kowerda, Anna, et al.
Publicado: (2015)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy
por: Jaroszewicz, Jerzy, et al.
Publicado: (2022)

High prevalence of anti-HEV antibodies among patients with immunosuppression and hepatic disorders in eastern Poland
por: Parfieniuk-Kowerda, Anna, et al.
Publicado: (2018)

Prevalence of HCV genotypes in Poland – the EpiTer study
por: Flisiak, Robert, et al.
Publicado: (2016)

Prevalence and Risk Factors of HCV/HIV Co-Infection and HCV Genotype Distribution in North-Eastern Poland
por: Grzeszczuk, Anna, et al.
Publicado: (2015)

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland
por: Pazgan-Simon, Monika, et al.
Publicado: (2023)

Effect of hepatitis B virus (HBV) infection on the course of pregnancy and newborns’ health status
por: Łapiński, Tadeusz Wojciech, et al.
Publicado: (2015)

Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study
por: Flisiak, Robert, et al.
Publicado: (2016)

Inflammatory and thrombotic parameters associated with the COVID-19 course in Poland (SARSTer study)
por: Czupryna, Piotr, et al.
Publicado: (2022)

Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland
por: Rzymski, Piotr, et al.
Publicado: (2022)

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
por: Flisiak, Robert, et al.
Publicado: (2021)

The interplay between Th17 and T-regulatory responses as well as adipokines in the progression of non-alcoholic fatty liver disease
por: Świderska, Magdalena, et al.
Publicado: (2017)

Chronic hepatitis B virus infection is associated with decreased serum 25(OH)D concentration in non-cirrhotic patients
por: Parfieniuk-Kowerda, Anna, et al.
Publicado: (2019)

Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease
por: Świderska, Magdalena, et al.
Publicado: (2017)

The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C
por: Domagalski, Krzysztof, et al.
Publicado: (2015)

HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B
por: Pawłowska, M., et al.
Publicado: (2011)

Control of HBV infection in HIV/HBV co-infected patients treated with antiretroviral therapy – experience of Lodz Centre
por: Wlazłowska, Ewelina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q2vraf14p8c6r7p38oav39egj7